HER2-negative Breast Cancer

Oncology
3
Pipeline Programs
4
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
1 program
1
E7389Phase 31 trial
Active Trials
NCT02225470Completed530Est. Jun 2018
Adagene
AdageneJIANGSU, China
1 program
1
ADG106Phase 1/21 trial
Active Trials
NCT05275777Active Not Recruiting66Est. Feb 2030
Celldex Therapeutics
1 program
1
PLD ChemotherapyPhase 11 trial
Active Trials
NCT05029999Recruiting30Est. Apr 2026
GS
Gilead SciencesFOSTER CITY, CA
2 programs
Specimen collectionN/A1 trial
Specimen collectionN/A
Active Trials
NCT06774027Recruiting100Est. Dec 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
EisaiE7389
AdageneADG106
Celldex TherapeuticsPLD Chemotherapy
Gilead SciencesSpecimen collection

Clinical Trials (4)

Total enrollment: 726 patients across 4 trials

NCT02225470EisaiE7389

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Start: Sep 2013Est. completion: Jun 2018530 patients
Phase 3Completed
NCT05275777AdageneADG106

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Start: May 2022Est. completion: Feb 203066 patients
Phase 1/2Active Not Recruiting
NCT05029999Celldex TherapeuticsPLD Chemotherapy

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Start: Apr 2022Est. completion: Apr 202630 patients
Phase 1Recruiting
NCT06774027Gilead SciencesSpecimen collection

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Start: Oct 2025Est. completion: Dec 2030100 patients
N/ARecruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
8m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
8m ago

Office Administrator

SystImmune
8m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
19m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
22m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
22m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 726 patients
4 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)